Equities

Imricor Medical Systems Inc

IMR:ASX

Imricor Medical Systems Inc

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.825
  • Today's Change0.015 / 1.85%
  • Shares traded117.10k
  • 1 Year change+41.99%
  • Beta0.8508
Data delayed at least 20 minutes, as of Nov 18 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Imricor Medical Systems Inc share price to rise to 1.08 in the next year from the last price of 0.825.
High31.3%1.08
Med31.3%1.08
Low31.3%1.08

Earnings history & estimates in USD

Imricor Medical Systems Inc reported annual 2022 losses of -0.116 per share on Feb 22, 2023.
Average growth rate-7.76%
More ▼

Revenue history & estimates in USD

Imricor Medical Systems, Inc. had revenues for the full year 2022 of 816.00k. This was 17.24% above the prior year's results.
Average growth rate+8.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.